Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

PURPOSE: Long-acting injectable (LAI) antipsychotic paliperidone palmitate 3-month formulation (PP3M) is indicated in the United States for the treatment of schizophrenia only after adequate treatment with paliperidone palmitate 1-month formulation (PP1M) for ≥4 months. This analysis aimed to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Abigail I, Turkoz, Ibrahim, Savitz, Adam J, Mathews, Maju, Kim, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435125/
https://www.ncbi.nlm.nih.gov/pubmed/30962688
http://dx.doi.org/10.2147/NDT.S194264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435125/
https://www.ncbi.nlm.nih.gov/pubmed/30962688
http://dx.doi.org/10.2147/NDT.S194264

Ejemplares similares